FDA Approves CHILDRENS XYZAL ALLERGY — Chattem, Inc.

# FDA Approves Chattem's Children's Xyzal Allergy Formulation Chattem, Inc. received FDA approval for Children's Xyzal Allergy (levocetirizine dihydrochloride) oral formulation on January 31, 2017, expanding its pediatric allergy portfolio in a competitive over-the-counter antihistamine market. The approval positions Chattem to capture additional market share in the growing children's allergy medication segment, where levocetirizine-based products continue to drive consumer demand.